Clinical research of dose - dense combinated pharmorubicin with paclitaxel in advanced breast cancer treatment
- VernacularTitle:表阿霉素联合紫杉醇密集化疗治疗晚期乳腺癌的临床研究
- Author:
Xiaohua ZENG
- Publication Type:Journal Article
- Keywords:
breast tumor;
pharmorubicin;
paclitaxel;
dose - dense
- From:
Journal of Chongqing Medical University
2003;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose;To observe curative effect and side reaction ,histopathology change of dose - dense combinated pharmorubicin with paclitaxel in advanced breast cancer treatment. Methods ;38 patients with advanced breast cancer diagnosed by pathology, which had e-valuation index, pharmorubicin 50mg/m2 ,d1 , intravenous injection,paclitaxel 175mg/m2,d2,intravenous injection,every 2 weeks as 1 course of treatment,after accepted 2 - 4 course of treatment,all patients were evaluated. Results: All patients were followed up,clinical complete remission( CR) 10. 5% , clinical partial remission 71. 1% , total effective rate 81. 6% . effective rate in patents of initial treatment was much higher than that in patients of retreatmen; effective rate in patents of III stage also was much higher than that in patients of IV stage; low leucocyte and Neutropenia appeared III ,IV side reaction,occupying respectively 63.2% and 71. 1% ;7.9% patients febricity owing to low leucocyte were cured by G - CSF and antibiotics,all patients successfully accomplish chemotherapy. Other side reaction,for instance thrombocytopenia.anaemia,nausea and vomiting etc,mostly displayed I , II toxic reaction,but they can be tolerated. After chemotherapy,cancer cells degeneration . cellular necrosis . retrogression and interstitial fibrosis .inflammatory cell infiltration are obviously changed. Conclusion: dose -dense chemotherapy combinated pharmorubicin with paclitaxel in advanced breast cancer treatment, remission rate was much higher and remission rate can be tolerated.
